Swedish Cancer Institute-Issaquah — Issaquah, Washington

Swedish Cancer Institute-Issaquah is a clinical research site located in Issaquah, Washington, United States 98029.

Crixeo Clinical Trials Trust Score: 35/100 (FAILING). This profile has not yet been claimed by the site owner.

Swedish Cancer Institute-Issaquah has participated in 270 clinical trials with 182 currently active.

Therapeutic areas: Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma.

Sponsors: National Cancer Institute (NCI), Alliance for Clinical Trials in Oncology, ECOG-ACRIN Cancer Research Group.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Issaquah

Browse all research sites in Washington · View every site in Issaquah

Sponsor Feasibility Report

Trust Score: 35/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Swedish Cancer Institute-Issaquah?

Swedish Cancer Institute-Issaquah has a Crixeo Trust Score of 35/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Swedish Cancer Institute-Issaquah conducted?

Swedish Cancer Institute-Issaquah has 270 clinical trials on record, with 182 currently active. Their work covers Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma.

Is Swedish Cancer Institute-Issaquah accredited by Crixeo Clinical Trials?

Swedish Cancer Institute-Issaquah has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Swedish Cancer Institute-Issaquah?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.